Presentation
Regulatory & Policy Considerations for Mpox Vaccines in African Countries
In the African region, mpox vaccination was first rolled out by DRC in October 2024 as part of their overall strategy to stop active transmission. To date, four countries (DRC, Nigeria, Rwanda and CAR) have rolled out vaccination. Mpox vaccination, however, has been largely limited to adults above 18 years in the four countries as per the Emergency Use Authorization granted by the national regulatory authorities. This was mainly because the EUAs were granted when the evidence in children below 12 years was still limited. Other countries that are yet to start vaccination also have EUAs for use among adults 18 years and above.
As more evidence became available, The MVA-BN vaccine was authorized for use among children aged 12 years and above by the European Medicines Association (EMA) and subsequently prequalified by WHO for use among children 12 years and above. The WHO Strategic Advisory Group of Experts (SAGE) recommends the use of mpox vaccines among children at risk of exposure to mpox in outbreak settings when the benefits of vaccination outweigh the potential risks.
Cases of mpox have been reported among children in many of the countries with mpox cases. To break chains of transmission and contribute to stopping the outbreak, there is need to vaccinate children who are at high-risk of mpox. This presentation shares updates on regulatory considerations on use of MVA-BN among children to facilitate countries to update their regulatory authorization.
Languages
- English
Publication year
2025
Type
Presentation
Categories
- Vaccines & delivery devices
Diseases
- Mpox
Countries
- Africa
Organisations
- World Health Organization (WHO)
Tags
- Emergencies
- New vaccine introduction
- Policy and legislation
WHO Regions
- African Region
Mpox-Policy
You can find more information about "Mpox-Policy" in the following Hot Topics:
Mpox-Policy-FR
